Liverpool ChiroChem
Liverpool
About Liverpool ChiroChem
Liverpool ChiroChem (LCC) is a chemistry-based CRO that produces chiral small molecules for biotech/pharmaceutical R&D. Their specialist products can be used as building blocks, fragments and screening compounds to enable small molecule drug discovery. their chemical technologies provide efficient access to novel chiral building blocks for hit identification and hit-to-lead optimization. LCC’s catalytic methods give access to a wide range of chiral amines in excellent enantiomeric purity. Their initial focus is on the production and supply of chiral piperidines and other sp3-rich nitrogen heterocycles , which are of great importance to drug discovery and development due to their excellent pharmacokinetic properties e.g. improved solubility and bioavailability. LCC's technologies were developed through years of research in the areas of asymmetric hydrogenation and Pd-coupling. LCC now provide collaborate services with their customers to optimise key steps in synthetic routes.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $7.5M
- Funding stage: M&A
- Last round: Series Unknown (Apr 2021)
- Website: liverpoolchirochem.com
- Phone: +44 (0)151 794 2936
Industries & Categories
Biotechnology, Chemical, Health Care, Manufacturing, Medical
Social Profiles
Canonical: https://fsome.com/organization/liverpool-chirochem-69147 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.